In this phase 3 , multicenter , randomized , open-label study , patients were randomized ( 1:1 ) to 1 of the 2 groups : everolimus 1.5 mg ( targeted C0 of 3-8 ng/mL ) plus reduced-dose cyclosporine or mycophenolate mofetil 2 g/d plus standard-dose cyclosporine .